Formerly known as Field Trip Discovery, Reunion Neuroscience (TSX:REUN, Nasdaq:REUN) has announced the appointment of Greg Mayes as its new president and CEO.
Mayes will first focus on completing the company’s Phase 1 clinical trial of its lead asset, RE-104 (formerly FT-104), for postpartum and treatment-resistant depression.
Mayes had held several senior executive roles at pharma companies, including a stint as president, CEO and founder of Engage Therapeutics from 2017 to 2020. From December 2020 to September 2022, he served as president and CEO of the clinical-stage biopharma Antios Therapeutics. At Antios, he led Series B financing worth more than $100 million.
In a LinkedIn post, Mayes described the new role at Reunion as an “ideal opportunity.” “I will be returning to my area of greatest interest and passion – the brain – where we successfully developed a rapid epileptic seizure treatment at Engage Therapeutics through Phase 2 and ultimately sold …